The Novartis Q3 2026 results, published on 27 October 2026, carried three headlines that are easy to confuse: a failed Phase III trial, a $1.9 billion accounting charge and a raised profit outlook. They are connected, but they are not the same thing. Novartis said its HARBOR study of del-desiran in myotonic dystrophy type 1 did not meet its primary endpoint, recorded a $1.9 billion partial impairment of the asset, and yet raised its 2026 guidance for core operating income. This article explains how those three facts fit together and what each one does and does not mean.
Key takeaways from the Novartis Q3 2026 results
- The Phase III HARBOR trial of del-desiran did not meet its primary endpoint, video hand opening time, against placebo in myotonic dystrophy type 1.
- Novartis booked a $1.9 billion partial impairment of the del-desiran in-process R&D asset, which was the main reason reported operating income fell 59% in US dollars to $1.84 billion.
- Core operating income, which excludes items such as impairments, rose 11% to $6.04 billion, and Novartis raised its full-year core operating income outlook.
- Net sales grew 4% to $14.52 billion, and the sales outlook of low single-digit growth was left unchanged.
- A second late-stage setback, for the heart drug pelacarsen, was also reported, but the company release gives no write-off figure for it.
What the HARBOR del-desiran Phase III trial found in the Novartis Q3 2026 results
Del-desiran is an experimental treatment for myotonic dystrophy type 1, often shortened to DM1, a rare inherited muscle disease. The HARBOR study compared del-desiran with placebo and used video hand opening time as its primary endpoint. That measure captures myotonia, the delayed muscle relaxation that makes it hard for patients to let go of a grip. According to Novartis, the trial did not meet that endpoint. The company also said it saw evidence of clinical activity in secondary endpoints and in exploratory analyses, and that it would evaluate the full dataset and speak to health authorities about the best path forward. Results will be presented at an upcoming medical congress.
The distinction matters. A missed primary endpoint means the trial did not show the effect it was designed to prove. Positive signals in secondary or exploratory analyses can guide a next study, but they do not support approval on their own. On the earnings call, executives said they still expect to need another Phase III study. Del-desiran remains an experimental therapy and is not approved for any use. Read the full release at the SEC filing or at novartis.com.
What a $1.9 billion impairment means in the Novartis Q3 2026 results
An impairment is an accounting adjustment, not a cash payment. When a company buys a drug candidate, the value is recorded as an intangible asset called in-process research and development. If new information lowers the expected value of that asset, the company writes part of it off. Novartis described the charge as a partial impairment, which means it still carries some value for del-desiran on its books. On the call, executives tied the size of the charge to a later timeline caused by the additional clinical work still to be done, and said the assumption is a similar chance of success with competition factored in. The charge sits in R&D expense.
No cash left the company because of the impairment itself. The money was spent when the asset was acquired. What the charge does is reduce reported profit in the quarter and signal that management now values the programme lower than before.
Why the Novartis Q3 2026 results show both a profit fall and a raised outlook
Novartis reports two sets of profit numbers. Reported, or IFRS, figures include everything, including the impairment. Core figures strip out items such as impairments and amortisation to show underlying performance. The gap between them explains the apparent contradiction.
- Reported operating income: $1,843 million, down 59% in US dollars from $4,501 million, with the margin falling to 12.7% of sales from 32.4%.
- Reported net income: $1,196 million, against $3,930 million a year earlier; earnings per share were $0.63, against $2.04.
- Core operating income: $6,036 million, up 11%, with a core margin of 41.6% against 39.3%.
- Core earnings per share: $2.46, up 9%.
- Free cash flow: $5.11 billion, down 18%.
By our own rough arithmetic, adding the $1.9 billion charge back to reported operating income gives about $3.7 billion, which is still below last year’s $4.5 billion. That is our calculation, not a company figure, and it shows other items also weighed on the quarter; Novartis cites higher R&D and other expense. For the full year, the company now expects core operating income to be in line with last year or to grow by a low single-digit percentage, upgraded from an earlier expectation of a low single-digit decline.
Pelacarsen in the Novartis Q3 2026 results and the $300 million question
The brief for this story mentioned a separate $300 million write-off linked to the heart drug pelacarsen. We could not confirm that figure in Novartis’s own release or its filing, so we do not report it as fact. What the company does say is that the Phase III HORIZON trial of pelacarsen did not meet its primary endpoint of reducing cardiovascular events in patients with elevated lipoprotein(a) and established cardiovascular disease, although the drug did lower lipoprotein(a). Further development is under review. If a specific write-off is later disclosed, we will update this article.
Background on myotonic dystrophy type 1
DM1 is a genetic disorder that affects muscles throughout the body and can involve the heart, eyes and other organs. It is caused by a repeat expansion in a gene called DMPK and is among the most common adult-onset muscular dystrophies. There is no approved therapy that treats the underlying cause, so care focuses on managing symptoms. General patient information is available from the US National Institute of Neurological Disorders and Stroke.
Market context from Acumen Research and Consulting
Rare neuromuscular disease sits within the wider musculoskeletal drugs market. Acumen Research and Consulting’s report Musculoskeletal Disorders Drugs Market values that market at USD 87.8 billion in 2022 and projects USD 135.3 billion by 2032, a CAGR of 4.5% from 2023 to 2032. It says North America held more than 33% of the market in 2022 and that Asia Pacific is the fastest-growing region, at more than 4.9% a year. The report is broad and was last updated in September 2023, and it does not size DM1 specifically, so it is background and not a forecast for del-desiran.
Timeline of the Novartis Q3 2026 results and the HARBOR setback
- 8 September 2026: press reports say the HARBOR failure was announced, and Novartis shares fell as much as 11% in Zurich that day.
- 27 October 2026: Novartis reports Q3 and nine-month results, books the $1.9 billion impairment and raises core operating income guidance.
- Upcoming: full HARBOR data at a medical congress and talks with health authorities.
General background: how drug failures reach the income statement
Pharmaceutical groups often buy late-stage assets at high prices. If a trial fails, accounting rules require them to test the asset’s value again. That is why a single study can produce a large charge months after the news. Press reports describe del-desiran as a centrepiece of Novartis’s roughly $12 billion acquisition of Avidity Biosciences, although the company’s results release does not discuss that deal. For related coverage, see our Novartis Abogen Deal: $7.8 Billion mRNA Autoimmune License report and the Pharmaceutical section.
Our analysis of the Novartis Q3 2026 results
In our assessment, the key lesson from the Novartis Q3 2026 results is that a failed trial, a write-down and a stronger outlook can all be true at once, because they measure different things. The trial result is scientific, the impairment is accounting, and the guidance reflects the rest of a very large business, where priority brands drove 4% sales growth. Readers should not treat the charge as a measure of how much cash was lost. Whether del-desiran has a future depends on the full HARBOR data and on what regulators accept for a next study.
What is not disclosed in the Novartis Q3 2026 results
- The full HARBOR dataset, including effect sizes and safety details.
- Any decision on a new Phase III study, its design or timing.
- Any separate pelacarsen write-off amount.
- The remaining carrying value of del-desiran after the impairment.
Risks and caveats
Guidance can change if trials, pricing or currency move against the company. The reported figures are from Novartis’s own release and have not been independently audited by us. Our arithmetic is illustrative. This article is news reporting and not investment or medical advice.
What to watch next after the Novartis Q3 2026 results
- The medical congress presentation of HARBOR and HORIZON data.
- Regulatory feedback on a new del-desiran study.
- Novartis’s November management event and full-year results.
- Competing DM1 programmes in development.
FAQ
Did Novartis lose $1.9 billion in cash?
No. The $1.9 billion is a non-cash impairment that reduced reported profit.
Is del-desiran approved?
No. It is an experimental treatment, and its Phase III trial missed its primary endpoint.
Why did Novartis raise its outlook?
Core operating income grew 11% in the quarter, and the guidance relates to core, not reported, profit.
How we reported this: we relied on Novartis’s results release and filing, the Acumen Research and Consulting report cited above and press reports, which we attribute. Our own calculations are labelled. Last updated 28 October 2026. This is news reporting and not advice.